Table 2.
Percentages of patients achieving combined endpoints in the two groups
| Combined endpoint | Dapagliflozin (n = 473) | GLP‐1RA (n = 336) | P | OR |
|---|---|---|---|---|
| Any reduction in HbA1c, BW and SBP, % | ||||
| Unadjusted | 31.3 | 29.8 | 0.642 | 1.05 (0.85–1.30) |
| MVA | 29.9 | 31.7 | 0.631 | 0.91 (0.64–1.30) |
| PSM (average n = 229/group) | 30.3 | 30.2 | 0.760 | 0.93 (0.61–1.44) |
| ΔHbA1c > 0.5%; ΔBW > 2 kg; ΔSBP>2 mm Hg, % | ||||
| Unadjusted | 16.9 | 17.3 | 0.897 | 0.98 (0.72–1.33) |
| MVA | 16.0 | 18.6 | 0.397 | 0.82 (0.53–1.27) |
| PSM (average n = 229/group) | 16.5 | 18.2 | 0.561 | 0.86 (0.53–1.41) |
| HbA1c ≤ 7.0%; ΔBW≥3%; SBP <140 mm Hg, % | ||||
| Unadjusted | 9.5 | 15.5 | 0.010 | 0.61 (0.42–0.89) |
| MVA | 10.5 | 14.0 | 0.187 | 0.71 (0.44–1.15) |
| PSM (average n = 229/group) | 12.6 | 17.7 | 0.183 | 0.70 (0.41–1.19) |
Note: The three composite endpoints are given and data are reported for unadjusted analysis (percentages observed in the entire cohort), for multivariable adjustment (percentages estimated from regression models) and for propensity score‐matched analysis (percentages observed in matched groups).
Note: Multivariable adjustment included the following variables: age, sex, diabetes duration, HbA1c, eGFR, concomitant use of metformin and insulin.
Abbreviations: BW, body weight; BMI, fasting plasma glucose; OR, odds ratio; SBP, systolic blood pressure.